

In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) -Global Forecast to 2027

Market Report | 2022-11-03 | 193 pages | MarketsandMarkets

AVAILABLE LICENSES:

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

Report description:

The global in situ hybridization market is projected to reach USD 2.8 billion by 2027 from USD 1.5 billion in 2022, at a CAGR of 12.6% during the forecast period. Companion diagnostic products showcase a significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a substantial role in developing companion diagnostics because of their ability to evaluate morphology and gene amplification simultaneously. This has increased the adoption of ISH-based consumables across companion diagnostic tests.

"The kits & reagents segment accounted for the highest share in the ISH consumables market revenue for the year 2021" The ISH market is segmented into 3 key products, namely, consumables, instruments, and software. The ISH consumables market is further segmented into kits & reagents, probes, and accessories. The advantages of kits are their ease of use, availability of ready-to-use reagents and antibodies, the optimized sensitivity of the antibody to an antigen, and decreased chances of errors. This has propelled the use of kits in diagnostic tools employed for cancer patients to identify eligibility for specific drugs during treatment.

"Hospitals & diagnostic laboratories accounted for the largest revenue share of the ISH market in 2021" Based on the end users the global in situ hybridization market is segmented into hospital & diagnostic laboratories, academic and research institutes, CROs, and pharmaceutical & biotechnology companies. Hospital & diagnostic laboratories segment has generated the highest revenue in 2021. The growing patient population, increasing Medicare reimbursement for clinical tests performed in hospitals, and the emergence of advanced diagnostic tests are some of the key factors driving the growth of this end-user segment.

?

"Asia Pacific: The fastest-growing country in the in situ hybridization market"

The in situ hybridization market is segmented into North America, Europe, Asia Pacific, RoW. The in situ hybridization market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests are the major factors driving market growth in the Asia Pacific. The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side- 80% and Demand Side 20% - By Designation: C-level - 25%, D-level - 20%, and Others - 55% By Region: North America -50%, Europe -20%, Asia-Pacific -20%, RoW -10% Lists of Companies Profiled in the Report: Abbott (US) - Abcam (UK) Abnova Corporation (Taiwan) - Agilent Technologies, Inc. (US) - Bio SB Inc. (US) - Biocare Medical, LLC (US) -∏BioCat GmbH (Germany) - BioGenex Laboratories (US) - Bio-Rad Laboratories (US) -∏Bio-Techne Corporation (US) - BioView (Israel) - Creative Bioarray (US) Danaher (US) - Enzo Biochem (US) -[]F. Hoffmann-La Roche AG (Switzerland) - GeneMed Biotechnologies Inc. (US) Merck KGaA (Germany) -∏NeoGenomics Laboratories (US) OpGen (US) -∏Oxford Gene Technology (UK) PerkinElmer Inc. (US) -[QIAGEN N.V. (Netherlands) - Thermo Fisher Scientific (US) - ZytoVision GmbH (Germany)

Research Coverage:

This report provides a detailed picture of the in situ hybridization market. It aims at estimating the size and future growth potential of the market across different segments, such as the product, technology, applications, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in situ hybridization market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints,

trends, opportunities, and challenges.

Table of Contents:

1 INTRODUCTION 31 1.1 STUDY OBJECTIVES 31 1.2 MARKET DEFINITION 32 1.2.1 INCLUSIONS & EXCLUSIONS 32 1.3 MARKET SCOPE 32 1.3.1 MARKETS COVERED 32 1.4 YEARS CONSIDERED 33 1.5 CURRENCY CONSIDERED 1.6 LIMITATIONS 33 1.7 STAKEHOLDERS 33 1.8 SUMMARY OF CHANGES 34 2 RESEARCH METHODOLOGY 35 2.1 RESEARCH DATA 35 FIGURE 1 RESEARCH DESIGN 35 2.1.1 SECONDARY DATA 35 2.1.2 PRIMARY DATA 36 FIGURE 2[BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET]37 2.2 MARKET ESTIMATION METHODOLOGY 37 FIGURE 3[MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)]37 FIGURE 4⊓IN SITU HYBRIDIZATION MARKET SIZE (USD MILLION)□38 FIGURE 5∏IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2022?2027)∏38 FIGURE 6[]IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, AND CHALLENGES[]39 2.3 MARKET DATA ESTIMATION & TRIANGULATION 40 2.3.1 DATA TRIANGULATION 40 FIGURE 7 DATA TRIANGULATION METHODOLOGY 40 2.4⊓INDUSTRY INSIGHTS∏41 2.5 RESEARCH ASSUMPTIONS 41 3 EXECUTIVE SUMMARY 42 FIGURE 8 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 42 FIGURE 9∏IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2022 VS. 2027 (USD MILLION)∏43 FIGURE 10 FLUORESCENT IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2021 43 FIGURE 11∏IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)∏44 FIGURE 12⊓IN SITU HYBRIDIZATION MARKET, BY END USER, 2022 VS. 2027 (USD MILLION)∏44 FIGURE 13 GEOGRAPHICAL SNAPSHOT OF IN SITU HYBRIDIZATION MARKET 45 4 PREMIUM INSIGHTS 46 4.1⊓IN SITU HYBRIDIZATION MARKET OVERVIEW∏46 FIGURE 14 GROWING FOCUS ON COMPANION DIAGNOSTICS AND RISING INCIDENCE OF CANCER & GENETIC DISORDERS TO DRIVE MARKET∏46 4.2 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET 46 FIGURE 15 CONSUMABLES TO COMMAND LARGEST SHARE IN 2021 46 4.3[IN SITU HYBRIDIZATION MARKET: BY REGION AND END USER, 2022 VS. 2027 (USD MILLION)[47 FIGURE 16 HOSPITALS & DIAGNOSTIC LABORATORIES SEGMENT TO GROW AT HIGHEST CAGR IN NORTH AMERICA 47 5 MARKET OVERVIEW 48

5.1 INTRODUCTION 48 5.2 MARKET DYNAMICS 48 FIGURE 17 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 48 TABLE 1 IN SITU HYBRIDIZATION MARKET: IMPACT ANALYSIS 49 5.2.1 DRIVERS 49 5.2.1.1 Rising incidence of genetic disorders and cancer 49 5.2.1.2 Growing awareness of companion diagnostics 49 5.2.2 OPPORTUNITIES 50 5.2.2.1 Emerging economies 50 5.2.3 CHALLENGES 50 5.2.3.1 Shortage of skilled professionals 50 5.3 PORTER'S FIVE FORCES ANALYSIS 50 TABLE 2⊓IN SITU HYBRIDIZATION MARKET: PORTER'S FIVE FORCES ANALYSIS⊓50 5.3.1 THREAT OF NEW ENTRANTS 51 5.3.2 THREAT OF SUBSTITUTES 51 5.3.3 BARGAINING POWER OF BUYERS 51 5.3.4 BARGAINING POWER OF SUPPLIERS 51 5.3.5 INTENSITY OF COMPETITIVE RIVALRY 51 5.4 SUPPLY CHAIN ANALYSIS 52 FIGURE 18 IN SITU HYBRIDIZATION MARKET: SUPPLY CHAIN 52 5.5 VALUE CHAIN ANALYSIS 53 FIGURE 19 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET 53 5.6 ECOSYSTEM ANALYSIS 54 FIGURE 20 IN SITU HYBRIDIZATION MARKET: ECOSYSTEM ANALYSIS 54 5.7 KEY CONFERENCES & EVENTS (2020?2022) 54 5.7.1□IN SITU HYBRIDIZATION CONFERENCES (2022)□54 TABLE 3□IN SITU HYBRIDIZATION CONFERENCES (2022)□54 5.7.2□IN SITU HYBRIDIZATION CONFERENCES (2021)□55 5.7.3 IN SITU HYBRIDIZATION CONFERENCES (2020) 55 TABLE 4⊓IN SITU HYBRIDIZATION CONFERENCES (2020)□55 5.8 REGULATORY ANALYSIS (IN SITU HYBRIDIZATION) 55 5.8.1 FDA APPROVALS 55 5.8.2 | REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS | 55 TABLE 5[]NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS[]55 TABLE 6[]EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS[]56 TABLE 7[]ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS[]56 TABLE 8 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57 5.9 PRICING ANALYSIS 57 TABLE 9 PRICING ANALYSIS OF IN SITU PRODUCTS 57 5.9.1∏IN SITU HYBRIDIZATION MARKET: AVERAGE SELLING PRICE TREND FOR TREATMENT∏58 6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT 59 6.1⊓INTRODUCTION⊓60 TABLE 10 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 60 6.2 CONSUMABLES 60 TABLE 11 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY TYPE, 2020-2027 (USD MILLION)[60 TABLE 12 IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY REGION, 2020-2027 (USD MILLION) 61 TABLE 13 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION) 61

TABLE 14 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION) 61 TABLE 15 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONSUMABLES, BY COUNTRY, 2020-2027 (USD MILLION) 62 6.2.1 PROBES 62

6.2.1.1[Preference for direct localization of DNA/RNA sequences using probes[]62

TABLE 16□IN SITU HYBRIDIZATION MARKET FOR PROBES, BY REGION, 2020-2027 (USD MILLION)□62

TABLE 17 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION) 63

TABLE 18 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION) 63

TABLE 19[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PROBES, BY COUNTRY, 2020-2027 (USD MILLION)[]63 6.2.2[]KITS & REAGENTS[]64

6.2.2.1 $\hfill\$ Growing focus on companion diagnostics to drive demand $\hfill\$ 64

TABLE 20[IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY REGION, 2020-2027 (USD MILLION)[64 TABLE 21[INORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)[64 TABLE 22[EUROPE: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)[65 TABLE 23[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR KITS & REAGENTS, BY COUNTRY, 2020-2027 (USD MILLION)][65 6.2.3][ACCESSORIES][65]

TABLE 24 IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY REGION, 2020-2027 (USD MILLION) 66 TABLE 25 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION) 66 TABLE 26 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION) 66 TABLE 27 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACCESSORIES, BY COUNTRY, 2020-2027 (USD MILLION) 67 6.3 INSTRUMENTS 67

6.3.1 RISING DEMAND FOR AUTOMATED SYSTEMS TO SUPPORT MARKET GROWTH 67

TABLE 28 IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY REGION, 2020-2027 (USD MILLION) 67 TABLE 29 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION) 68 TABLE 30 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION) 68 TABLE 31 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INSTRUMENTS, BY COUNTRY, 2020-2027 (USD MILLION) 68 6.4 SOFTWARE 69

6.4.1 RISING NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS TO DRIVE MARKET 69

TABLE 32[IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY REGION, 2020-2027 (USD MILLION)[]69 TABLE 33[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)[]69 TABLE 34[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)[]70 TABLE 35[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR SOFTWARE, BY COUNTRY, 2020-2027 (USD MILLION)[]70 7[]IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY[]71

7.1 INTRODUCTION 72

TABLE 36 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 72

7.2 FLUORESCENT IN SITU HYBRIDIZATION 72

TABLE 37 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 72

TABLE 38 FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION) 73

TABLE 39[]NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]73 TABLE 40[]EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]73 TABLE 41[]ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]74 7.2.1[]DNA FLUORESCENT IN SITU HYBRIDIZATION[]74

7.2.1.1 Rising need to ensure stability of genetic material to drive market 74

TABLE 42 DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION) 74

TABLE 43[NORTH AMERICA: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]75 TABLE 44[]EUROPE: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]75 TABLE 45[]ASIA PACIFIC: DNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]75 7.2.2[]RNA FLUORESCENT IN SITU HYBRIDIZATION[]76

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

7.2.2.1 Increasing biomedical research activity to support market growth 76

TABLE 46[]RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)[]76 TABLE 47[]NORTH AMERICA: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]76 TABLE 48[]EUROPE: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]77 TABLE 49[]ASIA PACIFIC: RNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]77 7.2.3[]PNA FLUORESCENT IN SITU HYBRIDIZATION[]77

7.2.3.1 Utilization of PNA FISH for infectious disease control to drive market 77

TABLE 50[]PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)[]78 TABLE 51[]NORTH AMERICA: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]78 TABLE 52[]EUROPE: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]78 TABLE 53[]ASIA PACIFIC: PNA FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]79 7.3[]CHROMOGENIC IN SITU HYBRIDIZATION][79

7.3.1 COST-EFFECTIVE ALTERNATIVE TO FISH TO SUPPORT MARKET GROWTH 79

TABLE 54[]CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)[]79 TABLE 55[]NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]80 TABLE 56[]EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]80 TABLE 57[]ASIA PACIFIC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]80 8]IN SITU HYBRIDIZATION MARKET, BY APPLICATION[]81

8.1 INTRODUCTION 82

TABLE 58[IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)]82

8.2 CANCER DIAGNOSTICS 82

8.2.1 INCREASING UTILIZATION OF FISH IN COMPANION DIAGNOSTICS TO DRIVE MARKET 82

TABLE 59[IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)[]82 TABLE 60[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)[]83

TABLE 61 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION) 83 TABLE 62 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION) 8.3 CYTOLOGY 84

8.3.1 IDENTIFICATION OF CYTOGENETIC ALTERATIONS TO DRIVE DEMAND FOR FISH 84

TABLE 63]IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION, 2020-2027 (USD MILLION)[]84 TABLE 64[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)[]84 TABLE 65[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)[]85 TABLE 66[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)[]85 8.4[]INFECTIOUS DISEASE DIAGNOSTICS[]86

8.4.1 RISING NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN EARLY DISEASE DIAGNOSIS TO SUPPORT MARKET [86 TABLE 67 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2020-2027 (USD MILLION)]86 TABLE 68 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)]86

TABLE 69[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION)]87

TABLE 70 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2020-2027 (USD MILLION) 87

8.5[]NEUROSCIENCE[]88

8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS TO DRIVE DEMAND FOR ISH 88

TABLE 71 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION, 2020-2027 (USD MILLION) 88

TABLE 72[NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)[]88 TABLE 73[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)[]89

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

TABLE 74[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2020-2027 (USD MILLION)[]89 8.6[]IMMUNOLOGY[]90

8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES TO SUPPORT MARKET 90

TABLE 75[IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION, 2020-2027 (USD MILLION)[]90

TABLE 76[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)[]90 TABLE 77[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)[]91

TABLE 78[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2020-2027 (USD MILLION)[]91 9[]IN SITU HYBRIDIZATION MARKET, BY END USER[]92

9.1 INTRODUCTION 93

TABLE 79[IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)]93

9.2 HOSPITALS AND DIAGNOSTIC LABORATORIES 93

9.2.1 HOSPITAL-BASED LABS ARE ACCESSIBLE AND OFFER RAPID TEST RESULTS 93

TABLE 80[]IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY REGION, 2020-2027 (USD MILLION)[]94

TABLE 81[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)[]94

TABLE 82[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)[]94

TABLE 83[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR HOSPITALS AND DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020-2027 (USD MILLION)]]95

9.3 ACADEMIC & RESEARCH INSTITUTES 95

9.3.1 INCREASING R&D ACTIVITIES FOR CHROMOSOMAL ABNORMALITIES TO SUPPORT MARKET GROWTH 95

TABLE 84[IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020-2027 (USD MILLION)[]95 TABLE 85[INORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)[]96

TABLE 86[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)[]96

TABLE 87□ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020-2027 (USD MILLION)□96

9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 97

9.4.1 RISING DEMAND FOR PRECISION TREATMENTS TO DRIVE MARKET 97

TABLE 88[]IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020-2027 (USD MILLION)[]97

TABLE 89[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)[]97

TABLE 90[]EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)[]98

TABLE 91[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020-2027 (USD MILLION)[]98

9.5 CONTRACT RESEARCH ORGANIZATIONS 98

9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 98

TABLE 92[IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2020-2027 (USD MILLION)[]99 TABLE 93[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)[]99

TABLE 94□EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027 (USD MILLION)□99

TABLE 95 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2020-2027

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

(USD MILLION)[100

10 IN SITU HYBRIDIZATION MARKET, BY REGION 101

10.1 INTRODUCTION 102

TABLE 96[]IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)[]102

10.2 NORTH AMERICA 103

FIGURE 21 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT 103

TABLE 97[NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]104 TABLE 98[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]104 TABLE 99[]NORTH AMERICA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]104 TABLE 100[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]105 TABLE 101[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]105 TABLE 102[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]105 TABLE 102[]NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027(USD MILLION)[]105 TABLE 103[]NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]106 10.2.1[]US[]106

10.2.1.1 Rising government funding for life science research to drive market 106

TABLE 104[JUS: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]106 TABLE 105[JUS: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]107 TABLE 106[JUS: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]107 TABLE 107[JUS: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]107 TABLE 108[JUS: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]108 TABLE 109[JUS: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]108 10.2.2[]CANADA[]108

10.2.2.1 Increasing investments in genomics research to drive market 108

TABLE 110 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 109 TABLE 111 CANADA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 109 TABLE 112 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 109 TABLE 113 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 100 TABLE 114 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 110 TABLE 114 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION) 110 TABLE 115 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 100 TABLE 115 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 100

TABLE 116[EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]111 TABLE 117[EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]111 TABLE 118[EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]111 TABLE 119[EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]112 TABLE 120[EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]112 TABLE 121[EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]112 TABLE 121[EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]112 TABLE 122[EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]113 10.3.1[]GERMANY[]113

10.3.1.1[Rising demand for technologically advanced diagnostic procedures to drive market[]113 TABLE 123[]GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]113 TABLE 124[]GERMANY: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]114 TABLE 125[]GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]114 TABLE 126[]GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]114 TABLE 127[]GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]114 TABLE 127[]GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]115 TABLE 128[]GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]115

10.3.2.1 Growing investments in proteomics and genomics to drive market 115

TABLE 129[]FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]116 TABLE 130[]FRANCE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]116 TABLE 131[]FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]116 TABLE 132[]FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]117 TABLE 133[]FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]117 TABLE 134[]FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]117 TABLE 134[]FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]117

10.3.3.1 Growing focus on cancer research to drive market for ISH 118

TABLE 135[]UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]118 TABLE 136[]UK: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]118 TABLE 137[]UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]119 TABLE 138[]UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]119 TABLE 139[]UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]119 TABLE 140[]UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]120 10.3.4[]REST OF EUROPE (ROE)[]120

TABLE 141[REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]120 TABLE 142[REST OF EUROPE: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]121 TABLE 143[REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]121 TABLE 144[REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]121 TABLE 145[REST OF EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]122 TABLE 146[REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]122 TABLE 146[REST OF EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]122

FIGURE 22[]ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT[]123

TABLE 147[[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2020-2027 (USD MILLION)[]124 TABLE 148[[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]124 TABLE 149[[ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]124 TABLE 150[[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)]]125 TABLE 151[[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)]]125 TABLE 152[[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)]]125 TABLE 152[[ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)]]125 TABLE 153[[ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)]]126 10.4.1[]]APAN]]126

10.4.1.1[Rising focus on personalized diagnostics products to support market growth[]126 TABLE 154[]APAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]126 TABLE 155[]APAN: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]127 TABLE 156[]APAN: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]127 TABLE 157[]APAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]127 TABLE 158[]APAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]127 TABLE 158[]APAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]128 TABLE 159[]APAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]128 10.4.2[]CHINA[]128

10.4.2.1 [Rising annual R&D investments to drive market demand for FISH and CISH-based kits]128 TABLE 160 [CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)]129 TABLE 161 [CHINA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)]129 TABLE 162 [CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)]129 TABLE 163 [CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)]130 TABLE 164 [CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)]130 TABLE 165 [CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)]130 TABLE 165 [CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)]130

10.4.3.1 Collaborations between hospitals and diagnostics centers for laboratory services to drive market 131 TABLE 166 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION) 131 TABLE 167 INDIA: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION) 131 TABLE 168 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION) 132 TABLE 169 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 132 TABLE 169 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 132 TABLE 170 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION) 132 TABLE 171 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 133 10.4.4 REST OF ASIA PACIFIC 133

TABLE 172[REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]133 TABLE 173[REST OF ASIA PACIFIC: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]134 TABLE 174[REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]134 TABLE 175[REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]134 TABLE 176[REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]134 TABLE 176[REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]135 TABLE 177[REST OF ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]135

TABLE 178[REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY REGION, 2020-2027 (USD MILLION)[]136 TABLE 179[REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY, 2020-2027 (USD MILLION)[]136 TABLE 180[REST OF THE WORLD: FLUORESCENT IN SITU HYBRIDIZATION MARKET, BY TYPE, 2020-2027 (USD MILLION)[]136 TABLE 181[REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY END USER, 2020-2027 (USD MILLION)[]137 TABLE 182[REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]137 TABLE 183[REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2020-2027 (USD MILLION)[]137 TABLE 183[REST OF THE WORLD: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2020-2027 (USD MILLION)[]137 TABLE 184[REST OF THE WORLD: IN SITU HYBRIDIZATION MARKET, BY APPLICATION, 2020-2027 (USD MILLION)[]138 11||COMPETITIVE LANDSCAPE||139

11.1 INTRODUCTION 139

11.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT-TO-WIN ANALYSIS 140

FIGURE 23[]IN SITU HYBRIDIZATION MARKET: STRATEGIES ADOPTED BY KEY PLAYERS[]140

11.3 MARKET SHARE ANALYSIS 141

FIGURE 24 IN SITU HYBRIDIZATION MARKET: MARKET SHARE ANALYSIS FOR KEY PLAYERS (2021) 141

11.4 REVENUE SHARE ANALYSIS 142

FIGURE 25 REVENUE ANALYSIS FOR KEY COMPANIES (2019?2021) 142

11.5 COMPANY EVALUATION QUADRANT 143

11.5.1[]STARS[]143

11.5.2 EMERGING LEADERS 143

11.5.3 PERVASIVE PLAYERS 143

11.5.4 PARTICIPANTS 143

FIGURE 26 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX (2021) 144

11.6 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 145

11.6.1 PROGRESSIVE COMPANIES 145

11.6.2 STARTING BLOCKS 145

11.6.3 RESPONSIVE COMPANIES 145

11.6.4 DYNAMIC COMPANIES 145

FIGURE 27 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION QUADRANT (2021) 146

11.6.5 COMPETITIVE BENCHMARKING 147

11.6.5.1 In situ hybridization market: Startups/SMEs 147

TABLE 185 LIST OIN SITU HYBRIDIZATION MARKET: STARTUPS/SMES 147

11.6.5.2 In situ hybridization market: Competitive benchmarking of key players [startups/SMEs) 148

TABLE 186[IN SITU HYBRIDIZATION MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS [STARTUPS/SMES]]148

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

11.7 COMPETITIVE SCENARIO AND TRENDS 149 11.7.1 DEALS 149 TABLE 187 IN SITU HYBRIDIZATION MARKET: DEALS 149 11.7.2 PRODUCT LAUNCHES 149 TABLE 188 IN SITU HYBRIDIZATION MARKET: PRODUCT LAUNCHES 149 12 COMPANY PROFILES 151 12.1 KEY COMPANIES 151 (Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)* 12.1.1 ABBOTT 151 TABLE 189 ABBOTT: BUSINESS OVERVIEW 151 FIGURE 28 ABBOTT: COMPANY SNAPSHOT 152 TABLE 190 ABBOTT: PRODUCTS OFFERED 152 12.1.2 F. HOFFMANN-LA ROCHE AG 154 TABLE 191 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW 154 FIGURE 29 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT 155 TABLE 192□F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED□155 TABLE 193□F. HOFFMANN-LA ROCHE LTD: PRODUCT APPROVALS□156 12.1.3 THERMO FISHER SCIENTIFIC INC. 157 TABLE 194 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 157 TABLE 195 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 158 12.1.4 DANAHER 161 TABLE 196 DANAHER: BUSINESS OVERVIEW 161 FIGURE 31 DANAHER: COMPANY SNAPSHOT 161 TABLE 197 DANAHER: PRODUCTS OFFERED 162 TABLE 198 PRODUCT APPROVALS 162 12.1.5 AGILENT TECHNOLOGIES, INC. 164 TABLE 199 AGILENT TECHNOLOGIES, INC: BUSINESS OVERVIEW 164 TABLE 200 AGILENT TECHNOLOGIES, INC: PRODUCTS OFFERED 165 12.1.6 BIOCARE MEDICAL, LLC 167 TABLE 201 BIOCARE MEDICAL, LLC: BUSINESS OVERVIEW 167 TABLE 202∏BIOCARE MEDICAL, LLC: PRODUCTS OFFERED∏167 12.1.7 BIO-TECHNE CORPORATION 169 TABLE 203 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW 169 TABLE 204 BIO-TECHNE: PRODUCT LAUNCHES 170 12.1.8 QIAGEN N.V. 171 TABLE 205 QIAGEN N.V.: BUSINESS OVERVIEW 171 TABLE 206 QIAGEN N.V.: PRODUCTS OFFERED 172 12.1.9 MERCK KGAA 173 TABLE 207 MERCK KGAA: BUSINESS OVERVIEW 173 TABLE 208 MERCK KGAA: PRODUCTS OFFERED 174 12.1.10 PERKINELMER 175 TABLE 209 PERKINELMER: BUSINESS OVERVIEW 175 TABLE 210 PERKINELMER: PRODUCTS OFFERED 176 12.1.11 ENZO BIOCHEM 177 TABLE 211 ENZO BIOCHEM: BUSINESS OVERVIEW 177 FIGURE 37 ENZO BIOCHEM: COMPANY SNAPSHOT 177

TABLE 212 ENZO BIOCHEM: PRODUCTS OFFERED 178 12.1.12 BIO-RAD LABORATORIES 179 TABLE 213 BIO-RAD LABORATORIES: BUSINESS OVERVIEW 179 TABLE 214 BIO-RAD LABORATORIES: PRODUCTS OFFERED 180 12.1.13 ABNOVA CORPORATION 181 TABLE 215 ABNOVA CORPORATION: BUSINESS OVERVIEW 181 TABLE 216 ABNOVA CORPORATION: PRODUCTS OFFERED 181 12.1.14 BIOGENEX LABORATORIES 182 TABLE 217 BIOGENEX LABORATORIES: BUSINESS OVERVIEW 182 TABLE 218 BIOGENEX LABORATORIES: PRODUCTS OFFERED 182 12.1.15 OPGEN 184 TABLE 219 OPGEN: BUSINESS OVERVIEW 184 TABLE 220 OPGEN INC: PRODUCTS OFFERED 185 12.1.16 BIO SB 186 TABLE 221 BIO SB: BUSINESS OVERVIEW 186 TABLE 222 BIO SB: PRODUCTS OFFERED 186 12.1.17 ABCAM 187 TABLE 223 ABCAM: BUSINESS OVERVIEW 187 TABLE 224 ABCAM: PRODUCTS OFFERED 188 12.1.18 ZYTOMED SYSTEMS GMBH 189 TABLE 225□ZYTOMED SYSTEMS GMBH: BUSINESS OVERVIEW□189 TABLE 226[]ZYTOMED SYSTEMS: PRODUCTS OFFERED[]189 12.1.19 NEOGENOMICS LABORATORIES 190 TABLE 227 NEOGENOMICS LABORATORIES: BUSINESS OVERVIEW 190 TABLE 228 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED 191 12.1.20 BIOVIEW 192 TABLE 229 BIOVIEW: BUSINESS OVERVIEW 192 TABLE 230 BIOVIEW: PRODUCTS OFFERED 192 *Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies. 12.2 OTHER PLAYERS 193 12.2.1 GENEMED BIOTECHNOLOGIES 193 TABLE 231 GENEMED BIOTECHNOLOGIES: BUSINESS OVERVIEW 193 12.2.2 CREATIVE BIOARRAY 193 TABLE 232 CREATIVE BIOARRAY: BUSINESS OVERVIEW 193 12.2.3 BIOCAT GMBH 194 TABLE 233 BIOCAT GMBH: BUSINESS OVERVIEW 194 12.2.4 OXFORD GENE TECHNOLOGY 194 TABLE 234 OXFORD GENE TECHNOLOGY: BUSINESS OVERVIEW 194 12.2.5 ZYTOVISION 194 TABLE 235 ZYTOVISION: BUSINESS OVERVIEW 194 13 APPENDIX 195 13.1 DISCUSSION GUIDE 195 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 198 13.3 CUSTOMIZATION OPTIONS 200 13.4 RELATED REPORTS 200 13.5 AUTHOR DETAILS 201



In Situ Hybridization Market by Products (Consumables, Instruments, Software), Technology (DNA FISH, RNA FISH, PNA FISH, CISH), Application (Cancer, Immunology, Neuroscience, Cytology), End User (Hospitals, Pharma, Biotech, CROs) -Global Forecast to 2027

Market Report | 2022-11-03 | 193 pages | MarketsandMarkets

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single User		\$4950.00
	Multi User		\$6650.00
	Corporate License		\$8150.00
	Enterprise Site License		\$10000.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP	number*
Address*	City*	

7in	Code*
Zip	Code

Country*

Date

2025-05-21

Signature